Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial
Authors:
- the Scandinavian Critical Care Trials GroupTGthe Scandinavian Critical Care Trials Group
- Anders PernerAPAnders Perner
- Nicolai HaaseNHNicolai Haase
- Jørn WetterslevJWJørn Wetterslev
- Anders ÅnemanAÅAnders Åneman
- Jyrki TenhunenJTJyrki Tenhunen
- Anne Berit GuttormsenAGAnne Berit Guttormsen
- Gudmundur KlemenzsonGKGudmundur Klemenzson
- Frank PottFPFrank Pott
- Karen Doris BødkerKBKaren Doris Bødker
- Per Martin BådstøløkkenPBPer Martin Bådstøløkken
- Asger BendtsenABAsger Bendtsen
Open Access
- 27 January 2011
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-9
Abstract
By tradition colloid solutions have been used to obtain fast circulatory stabilisation in shock, but high molecular weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis. Now lower molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICUs) and 1st choice fluid for patients with severe sepsis. However, HES 130/0.4 is largely unstudied in patients with severe sepsis. The 6S trial will randomise 800 patients with severe sepsis in 30 Scandinavian ICUs to masked fluid resuscitation using either 6% HES 130/0.4 in Ringer's acetate or Ringer's acetate alone. The composite endpoint of 90-day mortality or end-stage kidney failure is the primary outcome measure. The secondary outcome measures are severe bleeding or allergic reactions, organ failure, acute kidney failure, days alive without renal replacement therapy or ventilator support and 28-day and 1/2- and one-year mortality. The sample size will allow the detection of a 10% absolute difference between the two groups in the composite endpoint with a power of 80%. The 6S trial will provide important safety and efficacy data on the use of HES 130/0.4 in patients with severe sepsis. The effects on mortality, dialysis-dependency, time on ventilator, bleeding and markers of resuscitation, metabolism, kidney failure, and coagulation will be assessed. ClinicalTrials.gov: NCT00962156Keywords
This publication has 33 references indexed in Scilit:
- The Effects of Hydroxyethyl Starch 130/0.4 (6%) on Blood Loss and Use of Blood Products in Major Surgery: A Pooled Analysis of Randomized Clinical TrialsAnesthesia & Analgesia, 2008
- Preferences for colloid use in Scandinavian intensive care unitsActa Anaesthesiologica Scandinavica, 2008
- Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsisBMC Emergency Medicine, 2008
- Colloid solutions for fluid resuscitation2008
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Intensive Care Medicine, 2007
- Colloids versus crystalloids for fluid resuscitation in critically ill patients2007
- Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised studyThe Lancet, 2001
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992